195 CHURCH STREET, NEW HAVEN, CT
Trevi Therapeutics Approves Amended 2019 Stock Incentive Plan
Reports First Quarter 2026 Financial Results and Provides Business Updates
Annual Report to Security Holders
Announces Pricing of $150 Million Underwritten Offering of Common Stock
Reports Fourth Quarter and Year End 2025 Financial Results and Provides Business Updates
Other Events
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Reports Third Quarter 2025 Financial Results and Provides Business Updates
Q1
FY 2025
Q3
Q2
FY 2024
Prospectus filed pursuant to Rule 424(b)(5)
S-3ASR
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Amended Schedule 13D - Ownership Report
Amended Schedule 13G - Ownership Report